Home The Word Brain My Amedeo FAQ Privacy About   

As of October 2023, Amedeo had
12,263 active subscribers

  HIV Infection

  Free Subscription


5 AIDS Res Hum Retroviruses
3 Clin Infect Dis
1 Dermatology
11 HIV Med
2 J Acquir Immune Defic Syndr
3 J Infect Dis
2 J Virol
1 Lancet Infect Dis
2 Nat Med
8 PLoS One
1 PLoS Pathog

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles


  1. DIETRICH DK, Laidlaw E, Hammoud DA, Pau AK, et al
    Dramatic Improvement of MRI Abnormalities of HIV Encephalopathy after Suppressive Antiretroviral Therapy.
    AIDS. 2023;37:1339-1340.

  2. RACCAGNI AR, Diotallevi S, Lolatto R, Lucente MF, et al
    Viral blips and virologic failures following mpox vaccination with MVA-BN among people with HIV.
    AIDS. 2023 Sep 29. doi: 10.1097/QAD.0000000000003733.
    PubMed         Abstract available

  3. KILLION JA, Magana C, Cepeda JA, Vo A, et al
    Unit costs of needle and syringe program provision: a global systematic review and cost extrapolation.
    AIDS. 2023 Sep 29. doi: 10.1097/QAD.0000000000003718.
    PubMed         Abstract available

  4. ONYANGO DO, van der Sande MAB, Yuen CM, Were J, et al
    Biomarker-confirmed suboptimal adherence to isoniazid preventive therapy among children living with HIV in western Kenya.
    AIDS. 2023 Sep 29. doi: 10.1097/QAD.0000000000003719.
    PubMed         Abstract available

  5. PARRA-RODRIGUEZ L, O'halloran J, Wang Y, Jin W, et al
    Common antiretroviral combinations are associated with somatic depressive symptoms in women with HIV.
    AIDS. 2023 Sep 29. doi: 10.1097/QAD.0000000000003730.
    PubMed         Abstract available

  6. NUNES MC, Tamblyn A, Jose L, Ntsimane M, et al
    Immunogenicity of tetanus, diphtheria and acellular pertussis vaccination among pregnant women living with and without HIV.
    AIDS. 2023 Sep 29. doi: 10.1097/QAD.0000000000003731.
    PubMed         Abstract available

  7. GANDHI MM, Nguyen KL, Lake JE, Liao D, et al
    Proprotein convertase subtisilin/kexin 9 (PCSK9) levels decline with HCV therapy in people with HIV/HCV and correlate with inflammation.
    AIDS. 2023 Oct 2. doi: 10.1097/QAD.0000000000003739.
    PubMed         Abstract available

  8. SHEIRA LA, Wekesa P, Cohen CR, Weke E, et al
    Impact of a livelihood intervention on gender roles and relationship power among people living with HIV.
    AIDS. 2023 Oct 2. doi: 10.1097/QAD.0000000000003742.
    PubMed         Abstract available

  9. JOSHU CE, Calkins KL, Rudolph JE, Xu X, et al
    Lower endoscopy, early-onset and average-onset colon cancer among medicaid beneficiaries with and without HIV: A cohort study.
    AIDS. 2023 Oct 2. doi: 10.1097/QAD.0000000000003740.
    PubMed         Abstract available

  10. DIRAJLAL-FARGO S, Strah M, Ailstock K, Sattar A, et al
    Factors associated with insulin resistance in a longitudinal study of Ugandan youth with and without HIV.
    AIDS. 2023 Oct 2. doi: 10.1097/QAD.0000000000003741.
    PubMed         Abstract available

  11. NOIPERM P, Saelue P
    Predictive model for diagnostic yield of bone marrow examination in patients with HIV infection with fever.
    AIDS. 2023 Oct 4. doi: 10.1097/QAD.0000000000003744.
    PubMed         Abstract available

  12. ALBALAWI YA, Shull T, Virdi A, Subra C, et al
    CD4dimCD8bright T cells are inversely associated with neuro-inflammatory markers among people living with HIV.
    AIDS. 2023 Oct 4. doi: 10.1097/QAD.0000000000003743.
    PubMed         Abstract available

    AIDS Res Hum Retroviruses

  13. COHEN MAA, Bourgeois JA
    HIV Psychiatry - the Missing Link to HIV Prevention and Comprehensive Care.
    AIDS Res Hum Retroviruses. 2023 Oct 4. doi: 10.1089/AID.2022.0184.
    PubMed         Abstract available

  14. VAN PAASSEN P, Dijkstra M, Peay H, Rokx C, et al
    Perceptions of rapid ART initiation among participants of the Netherlands Cohort Study on Acute HIV infection.
    AIDS Res Hum Retroviruses. 2023 Oct 4. doi: 10.1089/AID.2022.0169.
    PubMed         Abstract available

  15. CASTELLI A, Lanzafame M, Morra M, Bertoldi M, et al
    Acceptability of switching to long acting cabotegravir and rilpivirine among people living with HIV on dolutegravir/rilpivirine combination: A single-center experience.
    AIDS Res Hum Retroviruses. 2023 Sep 30. doi: 10.1089/AID.2023.0070.
    PubMed         Abstract available

  16. FISHER S, Jao J, Yee LM, Serghides L, et al
    Association of fatty acid signatures with HIV viremia in pregnancy.
    AIDS Res Hum Retroviruses. 2023 Sep 29. doi: 10.1089/AID.2023.0040.
    PubMed         Abstract available

  17. SILVA NMD, Leite NPM, Carvalho AE, Almeida VD, et al
    AIDS Res Hum Retroviruses. 2023 Sep 29. doi: 10.1089/AID.2022.0178.
    PubMed         Abstract available

    Clin Infect Dis

  18. SAUER SM, Mitnick CD, Khan U, Hewison C, et al
    Estimating post-treatment recurrence after multidrug-resistant tuberculosis treatment among patients with and without HIV: the impact of assumptions about death and missing follow-up.
    Clin Infect Dis. 2023 Sep 29:ciad589. doi: 10.1093.
    PubMed         Abstract available

  19. SUNG J, Nantale M, Nalutaaya A, Biche P, et al
    Evidence for tuberculosis in individuals with Xpert Ultra "trace" sputum during screening of high-burden communities.
    Clin Infect Dis. 2023 Oct 3:ciad595. doi: 10.1093.
    PubMed         Abstract available

    My Personal Calling.
    Clin Infect Dis. 2023 Oct 4:ciad542. doi: 10.1093.


  21. IAMSUMANG W, Chanprapaph K, Sukasem C, Satapornpong P, et al
    Genotypic and phenotypic characteristics of co-trimoxazole-induced cutaneous adverse reactions.
    Dermatology. 2023 Oct 4. doi: 10.1159/000534342.
    PubMed         Abstract available

    HIV Med

  22. HOVAGUIMIAN F, Kouyos RD, Kusejko K, Schmidt AJ, et al
    Incidence of sexually transmitted infections and association with behavioural factors: Time-to-event analysis of a large pre-exposure prophylaxis (PrEP) cohort.
    HIV Med. 2023 Sep 28. doi: 10.1111/hiv.13543.
    PubMed         Abstract available

  23. DAUBY N, Motet C, Libois A, Martin C, et al
    The value of herpes zoster prevention in patients aging with HIV: A narrative review.
    HIV Med. 2023 Sep 29. doi: 10.1111/hiv.13548.
    PubMed         Abstract available

  24. RABEN D, Kahama CB, Combs L, Stengaard A, et al
    The use and impact of European Testing Week regional awareness campaigns to increase HIV and viral hepatitis testing coverage.
    HIV Med. 2023 Sep 29. doi: 10.1111/hiv.13544.
    PubMed         Abstract available

  25. COZZI-LEPRI A, Dunn D, Tostevin A, Marvig RL, et al
    Rate of response to initial antiretroviral therapy according to level of pre-existing HIV-1 drug resistance detected by next-generation sequencing in the strategic timing of antiretroviral treatment (START) study.
    HIV Med. 2023 Sep 29. doi: 10.1111/hiv.13556.
    PubMed         Abstract available

  26. GRAHAM EE, Michala L, Hatchfeld A, Moseholm E, et al
    Collection of menopause data in studies of women living with HIV: A systematic literature review.
    HIV Med. 2023 Sep 30. doi: 10.1111/hiv.13552.
    PubMed         Abstract available

  27. SUDOVEC-SOMOGYI JV, Krakauer F, Ferreira AA, Stabellini N, et al
    Heterogeneities of the impact of public health policies on HIV/AIDS indicators in Brazil according to sociodemographic factors: A real-life study.
    HIV Med. 2023 Sep 30. doi: 10.1111/hiv.13553.
    PubMed         Abstract available

  28. GIGUERE K, Chartrand-Lefebvre C, Baril JG, Conway B, et al
    Baseline characteristics of a prospective cohort study of aging and cardiovascular diseases among people living with HIV.
    HIV Med. 2023 Oct 1. doi: 10.1111/hiv.13550.
    PubMed         Abstract available

  29. KRINGS A, Schmidt D, Kollan C, Meixenberger K, et al
    Increasing hepatitis B vaccination coverage and decreasing hepatitis B co-infection prevalence among people with HIV-1 in Germany, 1996-2019. Results from a cohort study primarily in men who have sex with men.
    HIV Med. 2023 Oct 2. doi: 10.1111/hiv.13554.
    PubMed         Abstract available

  30. KOKORELIAS KM, Grosse A, Zhabokritsky A, Walmsley SL, et al
    Exploring implementation considerations for geriatric-HIV clinics: A secondary analysis from a scoping review on HIV models of geriatric care.
    HIV Med. 2023 Oct 4. doi: 10.1111/hiv.13549.
    PubMed         Abstract available

  31. GOODEN TE, Nirantharakumar K, Thomas GN
    Author reply: Letter to the editor on "A matched cohort study investigating premature, accentuated, and accelerated aging in people living with HIV".
    HIV Med. 2023 Oct 4. doi: 10.1111/hiv.13560.

  32. CHADWICK D, Hill-Tout R
    HIV medicine editorial: Opt-out HIV testing in the UK: Approaching the endgame?
    HIV Med. 2023 Oct 2. doi: 10.1111/hiv.13555.

    J Acquir Immune Defic Syndr

  33. CONVERY C, Diesel J, Brantley A, Miller J, et al
    Ryan White participation increased the prevalence of COVID-19 vaccination among PLWH in Michigan.
    J Acquir Immune Defic Syndr. 2023 Oct 5. doi: 10.1097/QAI.0000000000003315.
    PubMed         Abstract available

  34. ELLEN M, D FM, Inka A, Asa M, et al
    Perception and emotional experiences of infant feeding among women living with HIV in a high-income setting: A longitudinal mixed methods study.
    J Acquir Immune Defic Syndr. 2023 Oct 5. doi: 10.1097/QAI.0000000000003314.
    PubMed         Abstract available

    J Infect Dis

  35. LAU CY, Martinez-Orengo N, Lyndaker A, Flavahan K, et al
    Advances and Challenges in Molecular Imaging of Viral Infections.
    J Infect Dis. 2023;228.
    PubMed         Abstract available

  36. FALADE-NWULIA O, Lesko CR, Fojo AT, Keruly JC, et al
    Hepatitis C treatment in people living with HIV: Potential to eliminate disease and disparity.
    J Infect Dis. 2023 Oct 5:jiad433. doi: 10.1093.
    PubMed         Abstract available

  37. CHIRENJE ZM, Laher F, Dintwe O, Muyoyeta M, et al
    Protein dose-sparing effect of AS01B adjuvant in a randomized preventive HIV vaccine trial of ALVAC-HIV (vCP2438) and adjuvanted bivalent subtype C gp120.
    J Infect Dis. 2023 Oct 5:jiad434. doi: 10.1093.
    PubMed         Abstract available

    J Virol

  38. PINCUS SH, Stackhouse M, Watt C, Ober K, et al
    Soluble CD4 and low molecular weight CD4-mimetic compounds sensitize cells to be killed by anti-HIV cytotoxic immunoconjugates.
    J Virol. 2023 Sep 29:e0115423. doi: 10.1128/jvi.01154.
    PubMed         Abstract available

  39. LERNER G, Ding L, Spearman P
    Tryptophan-based motifs in the LLP3 region of the HIV-1 envelope glycoprotein cytoplasmic tail direct trafficking to the endosomal recycling compartment and mediate particle incorporation.
    J Virol. 2023 Oct 5:e0063123. doi: 10.1128/jvi.00631.
    PubMed         Abstract available


  40. HARRIS E
    Trial Launches of New HIV Vaccine Candidate With CMV Vector.
    JAMA. 2023 Oct 4. doi: 10.1001/jama.2023.19203.

    Lancet Infect Dis

  41. PINNETTI C, Cimini E, Mazzotta V, Matusali G, et al
    Mpox as AIDS-defining event with a severe and protracted course: clinical, immunological, and virological implications.
    Lancet Infect Dis. 2023 Sep 28:S1473-3099(23)00482.
    PubMed         Abstract available

    Nat Med

  42. MOORE M, Stansfield S, Donnell DJ, Boily MC, et al
    Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence.
    Nat Med. 2023 Oct 5. doi: 10.1038/s41591-023-02564.
    PubMed         Abstract available

  43. DASHTI A, Sukkestad S, Horner AM, Neja M, et al
    AZD5582 plus SIV-specific antibodies reduce lymph node viral reservoirs in antiretroviral therapy-suppressed macaques.
    Nat Med. 2023 Oct 2. doi: 10.1038/s41591-023-02570.
    PubMed         Abstract available

    PLoS One

  44. WINTERS N, Schnitzer ME, Campbell JR, Ripley S, et al
    Identifying patients with multidrug-resistant tuberculosis who may benefit from shorter durations of treatment.
    PLoS One. 2023;18:e0292106.
    PubMed         Abstract available

  45. IKWARA EA, Nakero L, Anyolitho MK, Isabirye R, et al
    Determinants of primary healthcare providers' readiness for integration of ART services at departmental levels: A case study of Lira City and District, Uganda.
    PLoS One. 2023;18:e0292545.
    PubMed         Abstract available

  46. MUSONDA E, Phiri M, Shasha L, Bwalya C, et al
    Prevalence of HIV testing uptake among the never-married young men (15-24) in sub-Saharan Africa: An analysis of demographic and health survey data (2015-2020).
    PLoS One. 2023;18:e0292182.
    PubMed         Abstract available

  47. ZERIHUN M, Mekonnen H, Gebretensaye TG
    Treatment outcome and associated factors among adult patients with pulmonary tuberculosis in selected health centers in Addis Ababa Ethiopia.
    PLoS One. 2023;18:e0292218.
    PubMed         Abstract available

  48. MNGUNI AT, Schietekat D, Ebrahim N, Sonday N, et al
    The interface between SARS-CoV-2 and non-communicable diseases (NCDs) in a high HIV/TB burden district level hospital setting, Cape Town, South Africa.
    PLoS One. 2023;18:e0277995.
    PubMed         Abstract available

  49. HAAS CB, Jordahl KM, Nance RM, Whitney BM, et al
    Assessing the associations between known genetic variants and substance use in people with HIV in the United States.
    PLoS One. 2023;18:e0292068.
    PubMed         Abstract available

  50. KIILU EM, Karanja S, Kikuvi G, Wanzala P, et al
    Prognostic factors influencing HIV-free survival among infants enrolled for HIV early infant diagnosis services in selected hospitals in Nairobi County, Kenya.
    PLoS One. 2023;18:e0292427.
    PubMed         Abstract available

  51. MENDOZA I, Lazaro A, Espinosa A, Sanchez L, et al
    Effectiveness, durability and safety of dolutegravir and lamivudine versus bictegravir, emtricitabine and tenofovir alafenamide in a real-world cohort of HIV-infected adults.
    PLoS One. 2023;18:e0291480.
    PubMed         Abstract available

    PLoS Pathog

  52. CHANDLER TL, Yang A, Otero CE, Permar SR, et al
    Protective mechanisms of nonneutralizing antiviral antibodies.
    PLoS Pathog. 2023;19:e1011670.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge.